Taken together, these results suggest that MCS-GM-CSF + IL-18 vaccine significantly enhanced antitumor efficacy and prolonged survival compared with either MCS-GM-CSF, MCS-IL-18 or LL/2 control group in the LL/2 mouse Lewis lung cancer model. The gene discussed is IL18; the disease is lung carcinoma.